Ocera Therapeutics has entered into a technology transfer and license deal with the Roche Group, including the Research and Early Development arms of both Genentech and Roche, for rights to its Macrocyclic Template Chemistry (MATCH) ...
Tags: Ocera Therapeutics, License Deal
Ocera Therapeutics (Nasdaq:OCRX) today announced that it has entered into a Technology Transfer and License Agreement with the Roche Group, including the Research and Early Development arms of both Genentech and Roche, for rights to its ...
Tags: Ocera Therapeutics, Roche, Macrocyclic Template Chemistry
Ventana Medical Systems (Ventana), a member of the Roche Group, has announced that its Ventana HER2/neu (4B5) rabbit monoclonal primary antibody assay is now a companion diagnostic for detecting HER2 protein expression for patients who, in ...
Tags: Ventana, Medical Systems
Ventana Medical Systems, a member of the Roche Group, has obtained the US Food and Drug Administration’s (FDA) 510(k) approval for its Companion Algorithm ER (SP1) image analysis algorithm used with the Ventana iScan Coreo scanner ...
Tags: Breast Cancer, Analysis Algorithm
Genentech, a member of the Roche Group, has announced that the US Food and Drug Administration (FDA) has accepted and filed the company's supplemental biologics license application (sBLA) for subcutaneous use of Xolair (omalizumab) in ...
Ventana Medical Systems,a member of the Roche Group, and pharmaceutical company Boehringer Ingelheim (BI) have entered into a collaboration agreement for the development of companion diagnostic tests for BI oncology programs. Companion ...
Oncology-focused drug development company Curis has obtained the conditional approval for Erivedge (vismodegib) to treat adult patients with symptomatic metastatic basal cell carcinoma (BCC) or locally advanced BCC inappropriate for surgery ...
Switzerland-based pharmaceuticals and diagnostics developer Roche has purchased US-based Constitution Medical Investors (CMI) for $220m, as part of its strategy to strengthen its hematology testing portfolio. CMI is a hematology testing ...
Tags: pharmaceuticals, diagnostics
Genentech, a member of the Roche Group, has obtained FDA priority review status for Obinutuzumab (GA101) to treat previously untreated chronic lymphocytic leukemia (CLL). The FDA has also accepted the company's biologics license ...
Tags: Genentech, FDA Priority
The Japanese Ministry of Health, Labour and Welfare (MHLW) has cleared Roche's Avastin (bevacizumab) as a combination therapy and monotherapy to treat the aggressive form of brain cancer glioblastoma. The first new medicine that is ...
Tags: Glioblastoma Therapy, Medicine
Roche Group member Genentech and Astellas Pharma US announced that the US Food and Drug Administration (FDA) has cleared Tarceva (erlotinib). The tablets are used for the initial treatment of people with metastatic non-small cell lung ...
Tags: FDA, Tarceva Tablets, Astellas Pharma
Roche Group recently declared cooperation with Ascletis in joint developing Danoprevir that is used for curing Hepatitis C, marking beginning of cooperative research and development, production and sale of new drugs in China with local ...
Vernalis has obtained a final payment of $2.5m from its drug discovery collaboration with Genentech, a member of the Roche Group. The collaboration was formed to discover novel small molecules for an undisclosed target using Vernalis' ...
Tags: Vernalis, drug discovery, drug
Roche Group member, Genentech has received US Food and Drug Administration (FDA) official approval of priority review designation for trastuzumab emtansine Biologics License Application (BLA). Trastuzumab Emtansine is designed to treat ...
Ventana Medical Systems, a member of the Roche Group, has launched a new fully-automated staining technique that allows researchers to visualize miRNAs and proteins related to cancer in the same section of tumor tissue. Detection of ...
Tags: Ventana, staining technique, cancer detection, miRNAs